Suppr超能文献

质子泵抑制剂与心血管疾病和心力衰竭风险增加的关联。

Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure.

机构信息

Department of Life Sciences, Optum, Eden Prairie, MN.

Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

出版信息

Mayo Clin Proc. 2021 Oct;96(10):2540-2549. doi: 10.1016/j.mayocp.2021.02.025.

Abstract

OBJECTIVE

To examine associations of cumulative exposure to proton pump inhibitors (PPIs) with total cardiovascular disease (CVD; composed of stroke, coronary heart disease, and heart failure [HF]) and HF alone in a cohort study of White and African American participants of the Atherosclerosis Risk in Communities (ARIC) study.

METHODS

Use of PPIs was assessed by pill bottle inspection at visit 1 (January 1, 1987 to 1989) and up to 10 additional times before baseline (visit 5; 2011 to 2013). We calculated cumulative exposure to PPIs as days of use from visit 1 to baseline. Participants (n=4346 free of total CVD at visit 5; mean age, 75 years) were observed for incident total CVD and HF events through December 31, 2016. We used Cox regression to measure associations of PPIs with total CVD and HF.

RESULTS

After adjustment for potential confounding variables, participants with a cumulative exposure to PPIs of more than 5.1 years had a 2.02-fold higher risk of total CVD (95% CI, 1.50 to 2.72) and a 2.21-fold higher risk of HF (95% CI, 1.51 to 3.23) than nonusers.

CONCLUSION

Long-term PPI use was associated with twice the risk of total CVD and HF compared with nonusers. Our findings are in concordance with other research and suggest another reason to be cautious of PPI overuse.

摘要

目的

在一项针对社区动脉粥样硬化风险研究(ARIC)中白人和非裔美国参与者的队列研究中,检查质子泵抑制剂(PPIs)累积暴露与总心血管疾病(CVD;包括中风、冠心病和心力衰竭[HF])和 HF 单独的关联。

方法

通过在第一次就诊(1987 年至 1989 年)时检查药瓶以及基线前的 10 次就诊(2011 年至 2013 年)评估 PPIs 的使用情况。我们将 PPIs 的累积暴露计算为从第一次就诊到基线的使用天数。参与者(n=4346,在第五次就诊时无总 CVD;平均年龄 75 岁)观察到总 CVD 和 HF 事件的发生,截至 2016 年 12 月 31 日。我们使用 Cox 回归来衡量 PPIs 与总 CVD 和 HF 的关联。

结果

在调整了潜在混杂变量后,累积暴露于 PPIs 超过 5.1 年的参与者发生总 CVD 的风险增加了 2.02 倍(95%CI,1.50 至 2.72),HF 的风险增加了 2.21 倍(95%CI,1.51 至 3.23),而非使用者。

结论

与非使用者相比,长期使用 PPI 与总 CVD 和 HF 的风险增加两倍有关。我们的研究结果与其他研究一致,表明 PPI 过度使用的另一个原因需要谨慎对待。

相似文献

1
Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure.
Mayo Clin Proc. 2021 Oct;96(10):2540-2549. doi: 10.1016/j.mayocp.2021.02.025.
3
Association between regular proton pump inhibitors use and cardiovascular outcomes: A large prospective cohort study.
Int J Cardiol. 2024 Jan 15;395:131567. doi: 10.1016/j.ijcard.2023.131567. Epub 2023 Nov 5.
4
Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study.
Neurology. 2023 Oct 31;101(18):e1771-e1778. doi: 10.1212/WNL.0000000000207747. Epub 2023 Aug 9.
5
Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study.
Circ Heart Fail. 2013 Sep 1;6(5):936-43. doi: 10.1161/CIRCHEARTFAILURE.113.000270. Epub 2013 Jul 16.
6
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
JAMA Intern Med. 2016 Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193.
7
Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes.
J Clin Endocrinol Metab. 2023 May 17;108(6):e216-e222. doi: 10.1210/clinem/dgac750.
8
Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure.
J Am Coll Cardiol. 2022 Feb 1;79(4):355-368. doi: 10.1016/j.jacc.2021.11.024.
9
Obesity and Subtypes of Incident Cardiovascular Disease.
J Am Heart Assoc. 2016 Jul 28;5(8):e003921. doi: 10.1161/JAHA.116.003921.
10
Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.
J Am Coll Cardiol. 2013 Apr 9;61(14):1510-7. doi: 10.1016/j.jacc.2013.01.022.

引用本文的文献

5
, esophageal precancerous lesions, and proton pump inhibitor overuse.
World J Gastroenterol. 2024 Nov 14;30(42):4591-4596. doi: 10.3748/wjg.v30.i42.4591.
6
Proton pump inhibitor use and risk of stroke: A systematic review and meta-analysis.
Pak J Med Sci. 2024 Nov;40(10):2432-2440. doi: 10.12669/pjms.40.10.10409.
7
Proton pump inhibitors and cardiovascular risk: a critical review.
Future Cardiol. 2024;20(14):779-794. doi: 10.1080/14796678.2024.2412910. Epub 2024 Oct 28.
8
Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR.
Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):99-119. doi: 10.5005/jp-journals-10018-1430.

本文引用的文献

1
Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel.
Aliment Pharmacol Ther. 2018 Oct;48(8):780-796. doi: 10.1111/apt.14955. Epub 2018 Sep 4.
3
No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication.
Gastroenterology. 2018 Apr;154(5):1290-1297.e1. doi: 10.1053/j.gastro.2017.12.006. Epub 2017 Dec 19.
5
Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.
Am J Gastroenterol. 2017 Jul;112(7):1084-1093. doi: 10.1038/ajg.2017.101. Epub 2017 Apr 11.
6
Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.
PLoS One. 2017 Jan 19;12(1):e0169826. doi: 10.1371/journal.pone.0169826. eCollection 2017.
9
Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.
Redox Biol. 2016 Oct;9:134-143. doi: 10.1016/j.redox.2016.08.001. Epub 2016 Aug 4.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验